Nearly all clinicians (95%) reported using off-label PAH monotherapy (in any line), including PDE-5i (87%), ERA (35%), PCA (25%) or sGC stimulators (11%) (figure 4). This evidence concerns the gene SGCB and pulmonary arterial hypertension.